New drug SUVN-I6107 tested in humans for first time
NCT ID NCT06705088
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety and tolerability of a new drug called SUVN-I6107 in 64 healthy adults. Participants received either the drug or a placebo tablet, and researchers monitored for side effects and how the drug moves through the body. The study also looked at brain activity changes using EEG. Since this is a first-in-human study, it does not aim to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SUVN-I6107
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Research Site
San Antonio, Texas, 78209, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test